CoChat

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

Open access
Rados, Dimitris Varvaki, Pinto, Lana Catani, Remonti, Luciana Reck, Leitão, Cristiane Bauermann, Gross, Jorge Luiz · 2016 · PLOS Medicine

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes. There is conflicting data about the safety of these drugs regarding mortality and cardiovascular outcomes. The objective of the present study was to evaluate the safety of the sulfonylureas most frequently used and to use trial sequential analysis (TSA) to analyze whether the available sample was powered enough to support the results. METHODS AND FINDINGS: Electronic databases were reviewed from 1946 (Embase) or 1966 (MEDLINE) up to 31 December 2014. Randomized clinical trials (RCTs) of at least 52 wk in duration evaluating second- or third-generation sulfonylureas in the treatment of adults with type 2 diabetes and reporting outcomes of interest were included. Primary outcomes were all-cause and cardiovascular mortality. Additionally, myocardial infarction and stroke events were evaluated. Data were summarized with Peto odds ratios (ORs), and the reliability of the results was evaluated with TSA. Forty-seven RCTs with 37,650 patients and 890 deaths in total were included. Sulfonylureas were not associated with all-cause (OR 1.12 [95% CI 0.96 to 1.30]) or cardiovascular mortality (OR 1.12 [95% CI 0.87 to 1.42]). Sulfonylureas were also not associated with increased risk of myocardial infarction (OR 0.92 [95% CI 0.76 to 1.12]) or stroke (OR 1.16 [95% CI 0.81 to 1.66]). TSA could discard an absolute difference of 0.5% between the treatments, which was considered the minimal clinically significant difference. The major limitation of this review was the inclusion of studies not designed to evaluate safety outcomes. CONCLUSIONS: Sulfonylureas are not associated with increased risk for all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. Current evidence supports the safety of sulfonylureas; an absolute risk of 0.5% could be firmly discarded. REVIEW REGISTRATION: PROSPERO CRD42014004330.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001992

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study flowchart.
Fig 1 Study flowchart.CC BY · PubMed Central
Fig 2 Forest plot for all-cause mortality. For studies with multiple treatment groups, the group being compared is presented in parentheses.
Fig 2 Forest plot for all-cause mortality. For studies with multiple treatment groups, the group being compared is presented in parentheses.CC BY · PubMed Central
Fig 3 Forest plots for all-cause mortality of sulfonylureas according to comparator (placebo/diet or active comparators). For studies with multiple treatment groups, the group being compared is presented in parentheses.
Fig 3 Forest plots for all-cause mortality of sulfonylureas according to comparator (placebo/diet or active comparators). For studies with multiple treatment groups, the group being compared is presented in parentheses.CC BY · PubMed Central
Fig 4 Forest plots for cardiovascular mortality of sulfonylureas according to comparator (placebo/diet or active comparators). For studies with multiple treatment groups, the group being compared is presented in parentheses.
Fig 4 Forest plots for cardiovascular mortality of sulfonylureas according to comparator (placebo/diet or active comparators). For studies with multiple treatment groups, the group being compared is presented in parentheses.CC BY · PubMed Central
Fig 5 Forest plots for all-cause and cardiovascular mortality of sulfonylureas as an add-on to metformin. For studies with multiple treatment groups, the group being compared is presented in parentheses.
Fig 5 Forest plots for all-cause and cardiovascular mortality of sulfonylureas as an add-on to metformin. For studies with multiple treatment groups, the group being compared is presented in parentheses.CC BY · PubMed Central
Fig 6 TSA for all-cause and cardiovascular mortality. TSA discarded harm with sulfonylurea use with an α of 5%, a β of 80%, and an absolute difference of 0.5% between the groups (sulfonylurea and comparator). The blue line represents the Z curve (cumulative effect size), the red dashed lines represent the harm, benefit, and futility boundaries and the estimated optimal sample size adjusted to sample size and repeated analysis, and the black lines represent the conventional confidence intervals. The black number and marking in the x-axis represent the number of patients accrued until that point. (A) Sulfonylureas overall for all-cause mortality. Futility and optimal sample size boundaries were crossed. (B) Sulfonylureas overall for cardiovascular mortality. Futility and optimal sample size boundaries were crossed. (C) Sulfonylureas as add-on to metformin for all-cause mortality. Futility and optimal sample size boundaries were crossed.
Fig 6 TSA for all-cause and cardiovascular mortality. TSA discarded harm with sulfonylurea use with an α of 5%, a β of 80%, and an absolute difference of 0.5% between the groups (sulfonylurea and comparator). The blue line represents the Z curve (cumulative effect size), the red dashed lines represent the harm, benefit, and futility boundaries and the estimated optimal sample size adjusted to sample size and repeated analysis, and the black lines represent the conventional confidence intervals. The black number and marking in the x-axis represent the number of patients accrued until that point. (A) Sulfonylureas overall for all-cause mortality. Futility and optimal sample size boundaries were crossed. (B) Sulfonylureas overall for cardiovascular mortality. Futility and optimal sample size boundaries were crossed. (C) Sulfonylureas as add-on to metformin for all-cause mortality. Futility and optimal sample size boundaries were crossed.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 102 references

Research works printed but not linked: 1

  1. MK Li, 1999, Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas, J Clin Int Med, 15, 38

Metadata

Authors
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L.
Affiliations
Universidade Federal do Rio Grande do Sul (BR)
Venue
PLOS Medicine
Published
2016-04-12
Volume
13
Issue
4
Pages
e1001992
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2341376576
Cited by
143
References
102
Citations by year
2026: 2 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 18 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 24 · 2016: 4
FWCI
3.34
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Americanae (AECID Library) (publishedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Funders
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
sulfonylureas, type 2 diabetes, drug safety, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, trial sequential analysis, sample size adequacy
MeSH terms
Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Time Factors, Chi-Square Distribution, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.1371/journal.pmed.1001992
The paper
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016). The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1001992

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.